Treatment of Metastatic Triple-Negative Breast Cancer
The Pharma Data
MARCH 25, 2021
The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines. Gilead Sciences, Inc. About the ASCENT Study.
Let's personalize your content